Atomoxetine was not originally included in that rogue’s gallery of medications, but since the drug was originally developed as an antidepressant, the FDA later reviewed its safety data. A post-hoc meta-analysis of placebo-controlled trials revealed an increased risk of suicidal thinking, and so atomoxetine was also slapped with a black box warning.

You can't view details of this content, please login or buy subscription here